Oruka Therapeutics, Inc.
ORKADrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 10, 2026
5dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ORKA Earnings Report
EPS Est: $-0.49 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ORKA's past catalysts played out
ORKA-001 Induction Dose
Plaque Psoriasis
ORKA-001
Plaque Psoriasis
ORKA-002
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ORKA-001 Induction Dose | Phase 2 | Plaque Psoriasis | - | - |
ORKA-001 | Phase 2 | Plaque Psoriasis | - | - |
ORKA-002 | Phase 2 | Plaque Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Oruka Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Oruka Therapeutics, Inc.'s (ORKA) pipeline across Phase 2. Its lead program is ORKA-001 Induction Dose (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oruka Therapeutics, Inc.'s next FDA catalyst?→
Oruka Therapeutics, Inc.'s (ORKA) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ORKA biotech catalysts?→
Add ORKA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oruka Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.